Compare KSS & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSS | TSHA |
|---|---|---|
| Founded | 1962 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 1995 | 2020 |
| Metric | KSS | TSHA |
|---|---|---|
| Price | $13.07 | $6.82 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $15.31 | $11.63 |
| AVG Volume (30 Days) | ★ 3.8M | 2.7M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | ★ 142.86 | 5.56 |
| EPS | ★ 2.38 | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.21 | $1,152.42 |
| P/E Ratio | $6.09 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $7.47 | $2.21 |
| 52 Week High | $25.22 | $7.30 |
| Indicator | KSS | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 38.20 | 65.73 |
| Support Level | $12.07 | $4.39 |
| Resistance Level | $16.82 | N/A |
| Average True Range (ATR) | 0.77 | 0.43 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 1.98 | 57.56 |
Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.